Skip to main content
SpringerLink
Log in

Drug/Agent Treatments for Osteoarthritis: Present and Future

  • Chapter
Osteoarthritis

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16:137–62.

    Article  CAS  PubMed  Google Scholar 

  3. Zhang W, Nuki G, Moskowitz RW, Abramson SB, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18:476–99.

    Article  CAS  PubMed  Google Scholar 

  4. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64:455–74.

    Article  Google Scholar 

  5. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis. 2004;63:901–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;(1):CD004257.

    Google Scholar 

  7. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;164:1519–24.

    Article  PubMed  Google Scholar 

  8. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med. 2007;167:394–9.

    Article  PubMed  Google Scholar 

  9. Rahme E, Barkun A, Nedjar H, Gaugris S, Watson D. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol. 2008;103:872–82.

    Article  CAS  PubMed  Google Scholar 

  10. Heard KJ, Green JL, Dart RC. Serum alanine aminotransferase elevation during 10 days of acetaminophen use in nondrinkers. Pharmacotherapy. 2010;30:818–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Miller M, Sturmer T, Azrael D, Levin R, Solomon DH. Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc. 2011;59:430–8.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2007;15:957–65.

    Article  CAS  PubMed  Google Scholar 

  13. Hochberg MC, Wohlreich M, Gaynor P, Hanna S, Risser R. Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. J Rheumatol. 2012;39:352–8.

    Article  CAS  PubMed  Google Scholar 

  14. Skljarevski V, Zhang S, Iyengar S, D’Souza D, Alaka K, Chappell A, et al. Efficacy of duloxetine in patients with chronic pain conditions. Curr Drug Ther. 2011;6:296–303.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31:2002–12.

    CAS  PubMed  Google Scholar 

  17. Underwood M, Ashby D, Cross P, Hennessy E, Letley L, Martin J, et al. Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. BMJ. 2008;336:138–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. McCleane G. The analgesic efficacy of topical capsaicin is enhanced by glyceryl trinitrate in painful osteoarthritis: a randomized, double blind, placebo controlled study. Eur J Pain. 2000;4:355–60.

    Article  CAS  PubMed  Google Scholar 

  19. Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoff CE. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin. 2004;20 Suppl 2:S13–9.

    Article  CAS  PubMed  Google Scholar 

  20. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2):CD005328.

    Google Scholar 

  21. Raynauld JP, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2003;48:370–7.

    Article  CAS  PubMed  Google Scholar 

  22. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2005;(2):CD005321.

    Google Scholar 

  23. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251–6.

    Article  CAS  PubMed  Google Scholar 

  24. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162:2113–23.

    Article  CAS  PubMed  Google Scholar 

  25. Bruyere O, Pavelka K, Rovati LC, Deroisy R, Olejarova M, Gatterova J, et al. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause. 2004;11:138–43.

    Article  PubMed  Google Scholar 

  26. Poolsup N, Suthisisang C, Channark P, Kittikulsuth W. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother. 2005;39:1080–7.

    Article  CAS  PubMed  Google Scholar 

  27. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 2010;30:357–63.

    Article  CAS  PubMed  Google Scholar 

  28. Hochberg MC, Zhan M, Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin. 2008;24:3029–35.

    Article  CAS  PubMed  Google Scholar 

  29. Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011;70:982–9.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43:2339–48.

    Article  CAS  PubMed  Google Scholar 

  31. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001;44:2539–47.

    Article  CAS  PubMed  Google Scholar 

  32. Maheu E, Mazieres B, Valat JP, Loyau G, Le Loet X, Bourgeois P, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum. 1998;41:81–91.

    Article  CAS  PubMed  Google Scholar 

  33. Maheu E, Cadet C, Marty M, Moyse D, Kerloch I, Coste P, et al. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014;73:376–84.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Nuesch E, Rutjes AW, Trelle S, Reichenbach S, Juni P. Doxycycline for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2009;(4):CD007323.

    Google Scholar 

  35. Jelic M, Pecina M, Haspl M, Kos J, Taylor K, Maticic D, et al. Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep. Growth Factors. 2001;19:101–13.

    Article  CAS  PubMed  Google Scholar 

  36. Gavenis K, Heussen N, Schmidt-Rohlfing B. Effects of low concentration BMP-7 on human osteoarthritic chondrocytes: comparison of different applications. J Biomater Appl. 2012;26:845–59.

    Article  CAS  PubMed  Google Scholar 

  37. Hunter DJ, Pike MC, Jonas BL, Kissin E, Krop J, McAlindon T. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord. 2010;11:232.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Moore EE, Bendele AM, Thompson DL, Littau A, Waggie KS, Reardon B, et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage. 2005;13:623–31.

    Article  CAS  PubMed  Google Scholar 

  39. Lohmander LS, Hellot S, Dreher D, Krantz EF, Kruger DS, Guermazi A, et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66:1820–31.

    Article  CAS  PubMed  Google Scholar 

  40. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91:4–15.

    CAS  PubMed  Google Scholar 

  41. Dhillon RS, Schwarz EM, Maloney MD. Platelet-rich plasma therapy – future or trend? Arthritis Res Ther. 2012;14:219.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med. 2013;41:356–64.

    Article  PubMed  Google Scholar 

  43. Taylor DW, Petrera M, Hendry M, Theodoropoulos JS. A systematic review of the use of platelet-rich plasma in sports medicine as a new treatment for tendon and ligament injuries. Clin J Sport Med. 2011;21:344–52.

    Article  PubMed  Google Scholar 

  44. Kon E, Mandelbaum B, Buda R, Filardo G, Delcogliano M, Timoncini A, et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. Arthroscopy. 2011;27:1490–501.

    Article  PubMed  Google Scholar 

  45. Kon E, Buda R, Filardo G, Di Martino A, Timoncini A, Cenacchi A, et al. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc. 2010;18:472–9.

    Article  PubMed  Google Scholar 

  46. Sampson S, Reed M, Silvers H, Meng M, Mandelbaum B. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil. 2010;89:961–9.

    Article  PubMed  Google Scholar 

  47. Sanchez M, Anitua E, Azofra J, Aguirre JJ, Andia I. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. Clin Exp Rheumatol. 2008;26:910–3.

    CAS  PubMed  Google Scholar 

  48. Filardo G, Kon E, Di Martino A, Di Matteo B, Merli ML, Cenacchi A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord. 2012;13:229.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Sanchez M, Fiz N, Azofra J, Usabiaga J, Aduriz Recalde E, Garcia Gutierrez A, et al. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy. 2012;28:1070–8.

    Article  PubMed  Google Scholar 

  50. Martel-Pelletier J, Wildi LM, Pelletier JP. Future therapeutics for osteoarthritis. Bone. 2012;51:297–311.

    Article  CAS  PubMed  Google Scholar 

  51. Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR, Currie MG, et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum. 1998;41:1275–86.

    Article  CAS  PubMed  Google Scholar 

  52. Graverand MP, Clemmer RS, Redifer P, Brunell RM, Hayes CW, Brandt KD, et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013;72:187–95.

    Article  Google Scholar 

  53. Suri S, Walsh DA. Osteochondral alterations in osteoarthritis. Bone. 2012;51:204–11.

    Article  PubMed  Google Scholar 

  54. Kwan Tat S, Lajeunesse D, Pelletier JP, Martel-Pelletier J. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol. 2010;24:51–70.

    Article  PubMed  Google Scholar 

  55. Lajeunesse D, Pelletier JP, Martel-Pelletier J. Osteoporosis and osteoarthritis: bone is the common battle ground. Medicographia. 2010;32:391–8.

    Google Scholar 

  56. Pelletier JP, Troncy E, Bertaim T, Thibaud D, Goulet AC, Abram F, et al. Treatment with tiludronic acid helps reduce the development of experimental osteoarthritis lesions in dogs with anterior cruciate ligament transection followed by reconstructive surgery: a 1-year study with quantitative magnetic resonance imaging. J Rheumatol. 2011;38:118–28.

    Article  CAS  PubMed  Google Scholar 

  57. Moreau M, Rialland P, Pelletier JP, Martel-Pelletier J, Lajeunesse D, Boileau C, et al. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther. 2011;13:R98.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum. 2004;50:3516–25.

    Article  PubMed  Google Scholar 

  59. Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther. 2005;7:R625–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Bingham 3rd CO, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006;54:3494–507.

    Article  CAS  PubMed  Google Scholar 

  61. Laslett LL, Dore DA, Quinn SJ, Boon P, Ryan E, Winzenberg TM, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis. 2012;71:1322–8.

    Article  CAS  PubMed  Google Scholar 

  62. Tat SK, Pelletier JP, Mineau F, Caron J, Martel-Pelletier J. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone. 2011;49:559–67.

    Article  CAS  PubMed  Google Scholar 

  63. Henrotin Y, Labasse A, Zheng SX, Galais P, Tsouderos Y, Crielaard JM, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res. 2001;16:299–308.

    Article  CAS  PubMed  Google Scholar 

  64. Pelletier JP, Kapoor M, Fahmi H, Lajeunesse D, Blesius A, Maillet J, et al. Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1beta in the synovium. Ann Rheum Dis. 2013;72:250–7.

    Article  CAS  PubMed  Google Scholar 

  65. Bruyere O, Delferriere D, Roux C, Wark JD, Spector T, Devogelaer JP, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis. 2008;67:335–9.

    Article  CAS  PubMed  Google Scholar 

  66. Reginster JY, Badurski J, Bellamy N, Bensen W, Chapurlat R, Chevalier X, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis. 2013;72:179–86.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  67. Bruyere O, Reginster JY, Bellamy N, Chapurlat R, Richette P, Cooper C, et al. Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. Rheumatology (Oxford). 2014;53:1457–64.

    Article  Google Scholar 

  68. Pelletier JP, Roubille C, Raynauld JP, Abram F, Dorais M, Delorme P, et al. Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Ann Rheum Dis. 2015;74(2):422–9.

    Google Scholar 

  69. Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med. 2009;58:29–40.

    Article  CAS  PubMed  Google Scholar 

  70. Kwan Tat S, Pelletier JP, Lajeunesse D, Fahmi H, Lavigne M, Martel-Pelletier J. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol. 2008;26:295–304.

    CAS  PubMed  Google Scholar 

  71. Kwan Tat S, Amiable N, Pelletier JP, Boileau C, Lajeunesse D, Duval N, et al. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology (Oxford). 2009;48:1482–90.

    Article  Google Scholar 

  72. Pilichou A, Papassotiriou I, Michalakakou K, Fessatou S, Fandridis E, Papachristou G, et al. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin Biochem. 2008;41:746–9.

    Article  CAS  PubMed  Google Scholar 

  73. Kadri A, Ea HK, Bazille C, Hannouche D, Liote F, Cohen-Solal ME. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum. 2008;58:2379–86.

    Article  CAS  PubMed  Google Scholar 

  74. Josse R, Khan A, Ngui D, Shapiro M. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. Curr Med Res Opin. 2013;29:205–16.

    Article  CAS  PubMed  Google Scholar 

  75. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299–309.

    Article  CAS  PubMed  Google Scholar 

  76. Hayami T, Zhuo Y, Wesolowski GA, Pickarski M, le Duong T. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone. 2012;50:1250–9.

    Article  CAS  PubMed  Google Scholar 

  77. Sampson ER, Hilton MJ, Tian Y, Chen D, Schwarz EM, Mooney RA, et al. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis. Sci Transl Med. 2011;3:101ra93.

    Article  PubMed Central  PubMed  Google Scholar 

  78. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. Oral salmon calcitonin reduces Lequesne’s algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 2006;54:3205–11.

    Article  CAS  PubMed  Google Scholar 

  79. Esenyel M, Icagasioglu A, Esenyel CZ. Effects of calcitonin on knee osteoarthritis and quality of life. Rheumatol Int. 2013;33:423–7.

    Article  CAS  PubMed  Google Scholar 

  80. Karsdal MA, Alexandersen P, John MR, Loeffler J, Arnold M, Azria M, et al. Oral calcitonin demonstrated symptom-modifying efficacy and increased cartilage volume: results from a 2-year Phase 3 trial in patients with osteoarthritis of the knee. Osteoarthritis Cartilage. 2011;19:S35.

    Article  Google Scholar 

  81. Reginster JY, Pelousse F, Bruyere O. Safety concerns with the long-term management of osteoporosis. Expert Opin Drug Saf. 2013;12:507–22.

    Article  CAS  PubMed  Google Scholar 

  82. McAlindon T, LaValley M, Schneider E, Nuite M, Lee JY, Price LL, et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial. JAMA. 2013;309:155–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  83. Cao Y, Jones G, Cicuttini F, Winzenberg T, Wluka A, Sharman J, et al. Vitamin D supplementation in the management of knee osteoarthritis: study protocol for a randomized controlled trial. Trials. 2012;13:131.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33–42.

    Article  CAS  PubMed  Google Scholar 

  85. Wu X, Kondragunta V, Kornman KS, Wang H, Duff GW, Renner JB, et al. IL-1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort. Osteoarthritis Cartilage. 2013;21:930–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  86. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum. 1996;39:1535–44.

    Article  CAS  PubMed  Google Scholar 

  87. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol. 2005;32:1317–23.

    CAS  PubMed  Google Scholar 

  88. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009;61:344–52.

    Article  CAS  PubMed  Google Scholar 

  89. Bacconnier L, Jorgensen C, Fabre S. Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis. 2009;68:1078–9.

    Article  CAS  PubMed  Google Scholar 

  90. Cohen SB, Proudman S, Kivitz AJ, Burch FX, Donohue JP, Burstein D, et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther. 2011;13:R125.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  91. Chevalier X, Conrozier T, Richette P. Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy. Arthritis Res Ther. 2011;13:124.

    Article  PubMed Central  PubMed  Google Scholar 

  92. Xoma to stop testing drug as arthritis treatment. Reuters Health. 2014. Available at: http://www.reuters.com/article/2014/03/05/us-xoma-arthritisdrug-idUSBREA241IP20140305. Accessed 25 May 2015.

  93. Martel-Pelletier J, Pelletier JP. Osteoarthritis: a single injection of anakinra for treating knee OA? Nat Rev Rheumatol. 2009;5:363–4.

    Article  CAS  PubMed  Google Scholar 

  94. Yang KG, Raijmakers NJ, van Arkel ER, Caron JJ, Rijk PC, Willems WJ, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage. 2008;16:498–505.

    Article  Google Scholar 

  95. Baltzer AW, Moser C, Jansen SA, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage. 2009;17:152–60.

    Article  CAS  PubMed  Google Scholar 

  96. Fioravanti A, Fabbroni M, Cerase A, Galeazzi M. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int. 2009;29:961–5.

    Article  CAS  PubMed  Google Scholar 

  97. Maksymowych WP, Russell AS, Chiu P, Yan A, Jones N, Clare T, et al. Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. Arthritis Res Ther. 2012;14:R206.

    Article  PubMed Central  PubMed  Google Scholar 

  98. Verbruggen G, Wittoek R, Vander Cruyssen B, Elewaut D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis. 2012;71:891–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  99. Magnano MD, Chakravarty EF, Broudy C, Chung L, Kelman A, Hillygus J, et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol. 2007;34:1323–7.

    CAS  PubMed  Google Scholar 

  100. Chevalier X, Ravaud P, Maheu E, Baron G, Rialland A, Vergnaud P, et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2014-205348.

    PubMed  Google Scholar 

  101. Chevalier X, Eymard F, Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol. 2013;9:400–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada

    Camille Roubille MD, Jean-Pierre Pelletier MD & Johanne Martel-Pelletier PhD

Authors
  1. Camille Roubille MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Pierre Pelletier MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johanne Martel-Pelletier PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johanne Martel-Pelletier PhD .

Editor information

Editors and Affiliations

  1. Division of Genetics and Development, Toronto Western Research Institute, University Health Network and Department of Surgery, University of Toronto, Toronto, Ontario, Canada

    Mohit Kapoor

  2. Division of Orthopaedics, Toronto Western Hospital, Toronto, Ontario, Canada

    Nizar N. Mahomed

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Roubille, C., Pelletier, JP., Martel-Pelletier, J. (2015). Drug/Agent Treatments for Osteoarthritis: Present and Future. In: Kapoor, M., Mahomed, N. (eds) Osteoarthritis. Adis, Cham. https://doi.org/10.1007/978-3-319-19560-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19560-5_10

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-19559-9

  • Online ISBN: 978-3-319-19560-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation